LT3275438T - Kardiovaskulinių įvykių prevencijos būdai dislipideminėse populiacijose, turinčiose likutinę riziką - Google Patents

Kardiovaskulinių įvykių prevencijos būdai dislipideminėse populiacijose, turinčiose likutinę riziką

Info

Publication number
LT3275438T
LT3275438T LTEP17183806.3T LT17183806T LT3275438T LT 3275438 T LT3275438 T LT 3275438T LT 17183806 T LT17183806 T LT 17183806T LT 3275438 T LT3275438 T LT 3275438T
Authority
LT
Lithuania
Prior art keywords
dislipidemic
populations
prevention
methods
cardiovascular events
Prior art date
Application number
LTEP17183806.3T
Other languages
English (en)
Inventor
Ryu Oshima
Gary Gordon
Original Assignee
Kowa Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59506076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3275438(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kowa Company, Ltd. filed Critical Kowa Company, Ltd.
Publication of LT3275438T publication Critical patent/LT3275438T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP17183806.3T 2016-07-29 2017-07-28 Kardiovaskulinių įvykių prevencijos būdai dislipideminėse populiacijose, turinčiose likutinę riziką LT3275438T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662368245P 2016-07-29 2016-07-29
US201762462574P 2017-02-23 2017-02-23

Publications (1)

Publication Number Publication Date
LT3275438T true LT3275438T (lt) 2021-03-25

Family

ID=59506076

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP17183806.3T LT3275438T (lt) 2016-07-29 2017-07-28 Kardiovaskulinių įvykių prevencijos būdai dislipideminėse populiacijose, turinčiose likutinę riziką

Country Status (13)

Country Link
US (5) US10864198B2 (lt)
EP (2) EP3791872A1 (lt)
CY (1) CY1123833T1 (lt)
DK (1) DK3275438T3 (lt)
ES (1) ES2847168T5 (lt)
HR (1) HRP20210082T1 (lt)
HU (1) HUE053081T2 (lt)
LT (1) LT3275438T (lt)
PL (1) PL3275438T3 (lt)
PT (1) PT3275438T (lt)
RS (1) RS61403B1 (lt)
SI (1) SI3275438T1 (lt)
SM (1) SMT202100035T1 (lt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
EP4338805B1 (en) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US20190224169A1 (en) * 2017-12-21 2019-07-25 Kowa Company, Ltd. Methods of Treatment of Hypertriglyceridemia
US11446282B2 (en) 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US20210290598A1 (en) * 2018-05-08 2021-09-23 National University Corporation Okayama University Medicament useful for cardiovascular disease
SG11202101562UA (en) * 2018-08-17 2021-03-30 Amarin Pharmaceuticals Ie Ltd Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
EP3903781A4 (en) * 2018-12-27 2023-01-25 Kowa Company, Ltd. PHARMACEUTICAL PREPARATION
US20220096443A1 (en) * 2018-12-27 2022-03-31 Kowa Company, Ltd. Pharmaceutical composition
CA3177693A1 (en) * 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
KR20250034041A (ko) * 2022-07-15 2025-03-10 교와 가부시키가이샤 혈중 ldl 콜레스테롤 저하제
WO2024167964A1 (en) * 2023-02-08 2024-08-15 Kowa Company, Ltd. Methods of treating and preventing peripheral artery disease
WO2025137024A1 (en) * 2023-12-18 2025-06-26 The Brigham And Women's Hospital, Inc. Methods of treating cardiovascular disease associated with calcification
CN118873513B (zh) * 2024-08-13 2025-01-28 烟台大学 一种尼达尼布组合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009374B1 (ru) 2003-09-03 2007-12-28 Кова Ко., Лтд. Активирующее ppar соединение и содержащая его фармацевтическая композиция
TWI407955B (zh) * 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑

Also Published As

Publication number Publication date
RS61403B1 (sr) 2021-02-26
US20210077467A1 (en) 2021-03-18
ES2847168T5 (es) 2024-02-20
EP3791872A1 (en) 2021-03-17
US20180028505A1 (en) 2018-02-01
EP3275438B1 (en) 2020-10-28
EP3275438A1 (en) 2018-01-31
SI3275438T1 (sl) 2021-05-31
DK3275438T3 (da) 2021-01-18
CY1123833T1 (el) 2022-05-27
US10869859B2 (en) 2020-12-22
SMT202100035T1 (it) 2021-03-15
PL3275438T3 (pl) 2021-05-17
HRP20210082T1 (hr) 2021-03-05
HUE053081T2 (hu) 2021-06-28
US20180028506A1 (en) 2018-02-01
US20210069158A1 (en) 2021-03-11
PT3275438T (pt) 2021-01-25
US10864198B2 (en) 2020-12-15
ES2847168T3 (es) 2021-08-02
US20210085652A1 (en) 2021-03-25
EP3275438B2 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
LT3275438T (lt) Kardiovaskulinių įvykių prevencijos būdai dislipideminėse populiacijose, turinčiose likutinę riziką
NO2023013I1 (no) Combination of foslevodopa and foscarbidopa, each in all forms protected by the basic patent
IL266560A (en) Endophytes, related preparations and methods of using them
HUE050206T2 (hu) Titán ötvözet
KR20180084891A (ko) 구조 조성물 및 방법
DK3182975T3 (da) Tabletter med høj doseringsstyrke af rucaparib
GB201512203D0 (en) Agents,uses and methods
EP3317997C0 (en) QUANTUM TOKENS
GB201512215D0 (en) Agents,uses and methods
EP3362581A4 (en) ALUMINUM IRON ZIRCONIUM ALLOYS
DK3230481T3 (da) Ferritisk legering
DE112015003457A5 (de) Al-Gusslegierung
DE112017004089A5 (de) Al-Gusslegierung
GB201421949D0 (en) Alloy
EP3438306A4 (en) NI-FE-CR ALLOY
NO3050465T3 (no) Seating
DE112017006468A5 (de) Al-gusslegierung
GB201401906D0 (en) Alloy
SG10201501367SA (en) Escalator step and escalator having thereof
DE112017001083A5 (de) Al-Gusslegierung
DK3237407T3 (da) 3,5-diaminopyrazolkinasehæmmere
FR3038786B1 (fr) Goulotte
DE112016001950A5 (de) Sitzgruppe
BR112016029865A2 (pt) liga ferrosa
UA32568S (uk) Крісло-гойдалка